Trial Summary
This clinical trial will evaluate a novel anti-cancer agent in a limited number of dogs with hemangiosarcoma. All dogs will receive study drug; there is no placebo.
Dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood samples are collected throughout the study to assess the metabolism and biological activity of this drug.
During the course of the study, dogs will not be allowed any holistic therapy, chemotherapy, prednisone therapy, non-steroidal anti-inflammatory therapy or other investigational therapies …

Status: Closed
Trial Summary
Pet dogs that are enrolled in the study will receive a single dose of a novel, oral anti-cancer agent. Serial blood samples and lymph node aspirates will then be collected over a 24-hour period.  Patients will return for evaluation 7 days after the single dose of therapy is administered.
For participation, clients will receive $2000 towards oncology care.
Trial Eligibility

Client-owned pet dogs > 1 year of age, 10-45 kg, with life expectancy of > 1 month;
Informed owner consent prior to initiation of screening/treatment;
Histological or cytological diagnosis of non-Hodgkins lymphoma …

Trial Summary
A clinical trial to evaluate a novel anti-cancer therapy is now available. The study is designed into two phases. The initial phase will evaluate the safety of this drug in dogs with any measurable cancer (excluding hemangiosarcoma). The 2nd phase will evaluate the safety of this drug in dogs with hemangiosarcoma exclusively. No placebo is used.
In both phases, dogs will receive the study drug as daily, oral treatment with evaluations performed once weekly for the first 28 days, then once monthly. Blood sample collection and tumor biopsies are collected …